Stryker (SYK) Aperçu de l'action
Stryker Corporation est une entreprise de technologie médicale présente aux États-Unis et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 2/6 |
| Performances passées | 5/6 |
| Santé financière | 4/6 |
| Dividendes | 4/6 |
Récompenses
Analyse des risques
SYK Community Fair Values
Create NarrativeSee what 104 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Stryker Corporation Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$319.87 |
| Plus haut sur 52 semaines | US$404.87 |
| Plus bas sur 52 semaines | US$281.00 |
| Bêta | 0.78 |
| Variation sur 1 mois | 6.22% |
| Variation sur 3 mois | -6.83% |
| Variation sur 1 an | -17.86% |
| Variation sur 3 ans | 8.21% |
| Variation sur 5 ans | 21.78% |
| Évolution depuis l'introduction en bourse | 58,952.89% |
Nouvelles et mises à jour récentes
Recent updates
Stryker: Medtech On Sale, Benefiting From Industry Growth
Summary Stryker Corporation offers a compelling medtech investment, benefiting from robust industry growth and an innovation-led strategy. SYK trades at a 13% discount to fair value, with a forward P/E of 20.1 versus a 10-year average of 25.6. Consensus expects SYK’s adjusted diluted EPS to compound at 11.2% annually through 2028, supporting high single-digit dividend growth. Key risks include cybersecurity vulnerabilities and fierce competition, but SYK’s diversified portfolio and disciplined capital allocation underpin its long-term outlook. Read the full article on Seeking Alpha
SYK: Hospital Digitization And Cyber Resilience Will Support 2026 Recovery Prospects
Stryker's fair value estimate has been adjusted slightly lower to $386.80 from $389.24 as analysts temper price targets in response to lower utilization expectations, inflation headwinds, and more conservative long term margin and P/E assumptions. Analyst Commentary Recent Street research on Stryker has been active, with most updates focused on resetting price targets and reassessing long term assumptions around utilization, inflation, and margins.SYK: Hospital Digitization And Cyber Resilience Will Drive 2026 Rebound Potential
Analysts have trimmed Stryker's updated price target slightly, reflecting a minor change of about $0.11 and combining a series of recent target cuts from multiple firms with one modest increase, as they reassess assumptions around discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts who recently raised or affirmed higher targets highlight what they see as healthy fundamentals in U.S. medical technology, which they argue can support Stryker's growth assumptions that underpin current P/E expectations.SYK: Hospital Digitization And Cyber Resilience Will Support 2026 Upside
Analysts have nudged Stryker's fair value estimate lower to about $389 from roughly $419, as a wave of reduced price targets led by firms like Truist, Barclays and others has been paired with updated assumptions for slightly lower future P/E multiples, alongside higher projected revenue growth and profit margins. Analyst Commentary Recent research around Stryker has tilted more cautious, with a cluster of reduced price targets across multiple firms, offset by a smaller group of more supportive views.Stryker Corporation Just Missed Earnings - But Analysts Have Updated Their Models
As you might know, Stryker Corporation ( NYSE:SYK ) last week released its latest first-quarter, and things did not...SYK: Diversified Portfolio And Hospital Digitization Will Support 2026 Upside
Analysts have trimmed Stryker's fair value estimate by about $6 to $419, reflecting slightly higher discount rate assumptions, a modestly lower revenue growth outlook, and a slightly lower future P/E multiple, even as profit margin expectations are marginally higher. Analyst Commentary Recent Street research on Stryker shows a mix of optimism about the company’s long term growth drivers and caution around near term valuation and risk.SYK: Diversified Growth Drivers And Robotics Adoption Will Support 2026 Upside
The updated analyst price target for Stryker edges slightly higher to about $425 per share, as analysts balance recent target trims with continued support from firms highlighting a healthy U.S. medtech backdrop, diversified growth drivers, and potential near term catalysts. Analyst Commentary Recent research paints a mixed but generally constructive picture for Stryker, with several firms adjusting price targets and ratings as they reassess growth drivers, execution, and valuation against a still supportive U.S. medtech backdrop.SYK: Diversified Portfolio And Robotics Adoption Will Support 2026 Upside
Analysts have trimmed the Stryker fair value estimate by less than $1 to about $424 per share, reflecting a slightly higher discount rate and a modestly lower assumed future P/E multiple. Recent research cites mixed price target moves and differing views on near term catalysts and sector trends.SYK: Diversified Product Reach And Robotics Expansion Will Support 2026 Upside
The analyst fair value estimate for Stryker has edged up by about $0.50 to $424.90, as analysts factor in recent price target moves, including several Outperform ratings that highlight the company's broader product reach and diversified growth profile. Analyst Commentary Recent research on Stryker reflects a mix of optimism about the company’s growth profile and some caution on valuation and sector level risks.SYK: Diversified Medtech Portfolio And Robotics Execution Will Support 2026 Upside
Analysts made a modest trim to their blended Stryker price target, reflecting mixed recent revisions that range from higher targets up to $465 with Outperform ratings to lower targets near $390 and $399 with a Hold rating, as they weigh the company's broader product reach and expected sales and earnings trends against valuation and sector-level risks. Analyst Commentary Recent research on Stryker reflects a split view, with some analysts leaning into the growth story and others more guarded on valuation and sector risks.Stryker's (NYSE:SYK) Earnings Seem To Be Promising
Stryker Corporation's ( NYSE:SYK ) recent earnings report didn't offer any surprises, with the shares unchanged over...Stryker (NYSE:SYK) Is Due To Pay A Dividend Of $0.88
Stryker Corporation ( NYSE:SYK ) will pay a dividend of $0.88 on the 30th of April. This takes the annual payment to...SYK: Orthopedics And Robotics Execution Will Support 2026 Rebound In Medtech Sentiment
Analysts have reduced their fair value estimate for Stryker by about $3 to $424, reflecting slightly softer revenue growth assumptions, a future P/E multiple closer to 34, and a modestly higher profit margin outlook following recent mixed price target changes across Wall Street. Analyst Commentary Recent research coverage on Stryker reflects a mix of optimism and caution, with several firms adjusting price targets and ratings in different directions.SYK: Orthopedics And Robotics Execution Will Support 2026 Upside Potential
Analysts have inched their average price target on Stryker higher, with a modest fair value lift to about US$427.40, as they weigh mixed target changes across firms against ongoing views that the company remains a high quality large-cap MedTech name heading into 2026. Analyst Commentary Recent Street research on Stryker shows a split tape, with several firms lifting targets and ratings while others trim fair values or stay neutral.SYK: Orthopedics Strength And Robotics Adoption Will Support Long-Term Upside
Narrative Update: Stryker The analyst price target for Stryker has been adjusted slightly lower to reflect a fair value estimate of about $427.22. Analysts point to mixed but generally solid recent research that highlights compressed forward multiples, updated targets in the $390 to $453 range, and ongoing views of Stryker as a high quality large cap MedTech name, with attractive entry points and healthy procedure and CapEx trends into 2026.SYK: Expanding Orthopedics And Robotics Footprint Will Drive Long-Term Upside Potential
Analysts have modestly trimmed our fair value estimate for Stryker to approximately $428 from about $433 per share, reflecting a slightly higher discount rate and lower valuation multiple, even as they acknowledge improving revenue growth, rising profit margins, and continued operating leverage highlighted in recent research updates and investor day commentary. Analyst Commentary Street research on Stryker has been active in recent weeks, with modestly higher and lower price targets reflecting a balanced mix of optimism on execution and caution on MedTech sentiment and relative growth.Stryker (NYSE:SYK) Has Announced That It Will Be Increasing Its Dividend To $0.88
Stryker Corporation's ( NYSE:SYK ) periodic dividend will be increasing on the 30th of January to $0.88, with investors...Does Stryker (NYSE:SYK) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Investors Can Find Comfort In Stryker's (NYSE:SYK) Earnings Quality
NYSE:SYK 1 Year Share Price vs Fair Value Explore Stryker's Fair Values from the Community and select yours The most...Rendement pour les actionnaires
| SYK | US Medical Equipment | US Marché | |
|---|---|---|---|
| 7D | -3.0% | -1.9% | -2.0% |
| 1Y | -17.9% | -18.7% | 17.2% |
Rendement vs Industrie: SYK correspondait au secteur US Medical Equipment qui a rapporté -18.7 % au cours de l'année écoulée.
Rendement vs marché: SYK a sous-performé le marché US qui a rapporté 17.2 % au cours de l'année écoulée.
Volatilité des prix
| SYK volatility | |
|---|---|
| SYK Average Weekly Movement | 5.3% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: SYK n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de SYK ( 5% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1941 | 56,000 | Kevin Lobo | www.stryker.com |
Stryker Corporation est une entreprise de technologie médicale présente aux États-Unis et dans le monde entier. Son activité s'articule autour de deux segments : MedSurg and Neurotechnology et Orthopaedics. Le segment MedSurg and Neurotechnology propose des équipements chirurgicaux, des technologies de sécurité pour les patients et le personnel soignant, des systèmes de navigation, des systèmes d'endoscopie et de communication, des équipements de manutention des patients, des équipements médicaux d'urgence et des produits de soins intensifs jetables, des technologies de communication clinique et de plate-forme de soins virtuels assistés par intelligence artificielle, des produits mini-invasifs pour le traitement des accidents vasculaires cérébraux ischémiques et hémorragiques aigus et de la thromboembolie veineuse, des produits pour les procédures chirurgicales traditionnelles sur le cerveau et à crâne ouvert, et des produits orthobiologiques et de biochirurgie, notamment des greffons osseux synthétiques et des produits d'augmentation vertébrale.
Stryker Corporation Résumé des fondamentaux
| SYK statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$126.97b |
| Bénéfices(TTM) | US$3.34b |
| Recettes(TTM) | US$25.27b |
Le site SYK est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| SYK compte de résultat (TTM) | |
|---|---|
| Recettes | US$25.27b |
| Coût des recettes | US$8.92b |
| Marge brute | US$16.35b |
| Autres dépenses | US$13.01b |
| Les revenus | US$3.34b |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
Jul 30, 2026
| Résultat par action (EPS) | 8.70 |
| Marge brute | 64.70% |
| Marge bénéficiaire nette | 13.21% |
| Ratio dettes/capitaux propres | 64.1% |
Quelles ont été les performances à long terme de SYK?
Voir les performances historiques et les comparaisonsDividendes
Le site SYK verse-t-il des dividendes fiables ?
Voir SYK l'historique des dividendes et les indices de référence| Stryker dates des dividendes | |
|---|---|
| Date ex-dividende | Jun 30 2026 |
| Date de paiement du dividende | Jul 31 2026 |
| Jours jusqu'au dividende Ex | 19 days |
| Jours jusqu'à la date de paiement du dividende | 12 days |
Le site SYK verse-t-il des dividendes fiables ?
Voir SYK l'historique des dividendes et les indices de référenceAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/17 13:34 |
| Cours de l'action en fin de journée | 2026/07/17 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Stryker Corporation est couverte par 53 analystes. 26 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| David Toung | Argus Research Company |
| Jeffrey Johnson | Baird |
| Adam Feinstein | Barclays |